Atria Investments Inc Has $8.90 Million Stock Holdings in Danaher Co. (NYSE:DHR)

Atria Investments Inc trimmed its stake in shares of Danaher Co. (NYSE:DHR) by 6.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 38,763 shares of the conglomerate’s stock after selling 2,699 shares during the quarter. Atria Investments Inc’s holdings in Danaher were worth $8,898,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in DHR. FMR LLC boosted its holdings in Danaher by 15.8% during the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after purchasing an additional 3,217,631 shares in the last quarter. Van ECK Associates Corp boosted its holdings in Danaher by 6,862.7% during the fourth quarter. Van ECK Associates Corp now owns 929,868 shares of the conglomerate’s stock valued at $213,452,000 after purchasing an additional 916,513 shares in the last quarter. Proficio Capital Partners LLC boosted its holdings in Danaher by 29,287.7% during the fourth quarter. Proficio Capital Partners LLC now owns 588,929 shares of the conglomerate’s stock valued at $135,189,000 after purchasing an additional 586,925 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Danaher by 17.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after purchasing an additional 535,254 shares in the last quarter. Finally, Fisher Funds Management LTD acquired a new position in shares of Danaher in the 4th quarter worth approximately $120,718,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Performance

Shares of Danaher stock opened at $210.97 on Thursday. The firm has a fifty day moving average of $223.22 and a two-hundred day moving average of $243.63. The stock has a market capitalization of $150.78 billion, a price-to-earnings ratio of 39.96, a PEG ratio of 2.66 and a beta of 0.82. Danaher Co. has a 52 week low of $196.80 and a 52 week high of $281.70. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40.

Danaher (NYSE:DHR) last issued its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the previous year, the business posted $2.09 earnings per share. As a group, equities research analysts predict that Danaher Co. will post 7.63 EPS for the current year.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a $0.32 dividend. The ex-dividend date is Friday, March 28th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.61%. This is a boost from Danaher’s previous quarterly dividend of $0.27. Danaher’s dividend payout ratio is currently 24.24%.

Insider Activity at Danaher

In related news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now owns 20,230 shares in the company, valued at $4,534,149.90. This represents a 21.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 11.10% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on DHR. Citigroup reduced their target price on Danaher from $285.00 to $265.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price on the stock in a report on Friday, December 13th. Robert W. Baird reduced their target price on Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a report on Tuesday, January 28th. JPMorgan Chase & Co. reduced their target price on Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a report on Tuesday, January 28th. Finally, StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Seven analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and an average target price of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.